by The Tutu Team | Aug 24, 2017 | Uncategorized
Source: Pharma Times Novartis has announced the launch of its new breast cancer drug Kisqali in the UK today following a green light from European regulators. The selective cyclin-dependent kinase inhibitor can now be prescribed across Europe in combination with an... by The Tutu Team | Oct 11, 2016 | Uncategorized
246,660 women will be diagnosed with breast cancer in 2016, and 40,450 women will die from the disease, suggested the American Cancer Society. More than two-thirds of all breast cancers are hormone dependent. In a randomized, Phase III trial led by researchers at The... by The Tutu Team | Oct 10, 2016 | Uncategorized
IMAGE: This is Gabriel Hortobagyi, M.D. view more Copenhagen, Denmark – In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically... by The Tutu Team | Oct 10, 2016 | Uncategorized
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically improved progression-free survival (PFS) of post-menopausal women with hormone... 